Arena Pharmaceuticals (ARNA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arena Pharmaceuticals (ARNA)

ARNA 99.99

0.0%

Mar 15 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Harold Engstrom	7/13/2016 8:24:58 AM
	Read Replies (1) of 2274

Arena has 3 programs that is it now focused on: S1P/Ulcerative Colitis candidate (APD334/Entrasimod), for their Pulmonary Arterial Hypertension candidate (APD811/Ralinepag,) and its pain and fibrosis CB2 candidate (APD371.) Entrasimod and Ralinepag will have P2 results before next April (scheduled anyway.) Both look promising. The company recently scaled R&D way back and cut costs to the bone after Eisai pulled back its commitment to selling Arena's Belviq serotonin anti-obesity medication to the bare contractual minimum. There is still a chance that Belviq could succeed, but it will have to wait for CVOT (cardio-vascular outcomes trial) results in 2018. This huge 5 year study is meant to verify that the fenfluramine-phentermine CV issues ascribed to fenfluramine do not also manifest with lorcaserin (Belviq.) If CVOT trials prove that use of Belviq improves CV outcomes then perhaps it can become a successful drug and Eisai or another company will commit to selling. Recently, Arena registered a shelf. It may execute one any time (hopefully after news give the stock a little push.)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next